Pro Share Advisors LLC Caribou Biosciences, Inc. Transaction History

Pro Share Advisors LLC

$39.7 Billion
Q3 2024

A detailed history of Pro Share Advisors LLC transactions in Caribou Biosciences, Inc. stock. As of the latest transaction made, Pro Share Advisors LLC holds 20,886 shares of CRBU stock, worth $26,316. This represents 0.0% of its overall portfolio holdings.

Number of Shares

20,886

Previous 16,541 26.27%

Holding current value

$26,316

Previous $27,000 48.15%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$1.56 - $2.73 $6,778 - $11,861	4,345 Added 26.27%	20,886 $40,000
Q2 2024 Aug 13, 2024	SELL	$1.62 - $5.05 $7,072 - $22,048	-4,366 Reduced 20.88%	16,541 $27,000
Q1 2024 May 08, 2024	BUY	$4.82 - $8.26 $8,213 - $14,075	1,704 Added 8.87%	20,907 $107,000
Q4 2023 Feb 14, 2024	BUY	$3.58 - $6.25 $13,346 - $23,300	3,728 Added 24.09%	19,203 $110,000
Q3 2023 Nov 13, 2023	BUY	$4.08 - $8.14 $16,756 - $33,430	4,107 Added 36.13%	15,475 $73,000
Q2 2023 Aug 10, 2023	BUY	$4.04 - $5.47 $2,173 - $2,942	538 Added 4.97%	11,368 $48,000
Q1 2023 May 11, 2023	SELL	$4.3 - $7.78 $6,161 - $11,148	-1,433 Reduced 11.69%	10,830 $57,000
Q4 2022 Feb 02, 2023	BUY	$5.57 - $11.01 $5,363 - $10,602	963 Added 8.52%	12,263 $77,000
Q3 2022 Nov 04, 2022	BUY	$5.34 - $12.79 $2,707 - $6,484	507 Added 4.7%	11,300 $119,000
Q2 2022 Aug 01, 2022	SELL	$5.1 - $9.74 $25,362 - $48,437	-4,973 Reduced 31.54%	10,793 $59,000
Q1 2022 May 10, 2022	BUY	$8.42 - $15.32 $24,047 - $43,753	2,856 Added 22.12%	15,766 $145,000
Q4 2021 Feb 08, 2022	BUY	$14.59 - $23.26 $188,356 - $300,286	12,910 New	12,910 $195,000

Others Institutions Holding CRBU

# of Institutions

138

Shares Held

52.8M

Call Options Held

148K

Put Options Held

70.7K

View Full List

About Caribou Biosciences, Inc.

Ticker CRBU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,840,800
Market Cap $76.7M
Description
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...

More about CRBU

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.

Account

Pro Share Advisors LLC Caribou Biosciences, Inc. Transaction History